{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspart+insulin&page=2", "query": { "intervention": "Aspart insulin", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Aspart+insulin&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-29T04:26:45.690Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01680341", "title": "Comparison of the Efficacy and Safety of Two Different Dose Adjustment Regimens for Insulin Degludec/Insulin Aspart in Subjects With Type 2 Diabetes Mellitus Previously Treated With Insulin Glargine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin degludec/insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 272, "start_date": "2012-08-31", "completion_date": "2013-08-22", "has_results": true, "last_update_posted_date": "2018-04-02", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 28, "location_summary": "Goodyear, Arizona • Anaheim, California • Greenbrae, California + 24 more", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Spring Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01680341" }, { "nct_id": "NCT00106366", "title": "Comparison of Insulin Detemir With Insulin Glargine in Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "insulin detemir", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 389, "start_date": "2005-03", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2017-01-31", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 68, "location_summary": "Birmingham, Alabama • Vestavia Hills, Alabama • Little Rock, Arkansas + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Vestavia Hills", "state": "Alabama" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Searcy", "state": "Arkansas" }, { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00106366" }, { "nct_id": "NCT00591227", "title": "Management of Diabetes in the Emergency Room: a Randomized Trial of an Insulin Protocol.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes Mellitus" ], "interventions": [ { "name": "insulin aspart", "type": "DRUG" }, { "name": "insulin detemir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Rush University Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 176, "start_date": "2008-05", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2022-02-07", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00591227" }, { "nct_id": "NCT00982228", "title": "Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 629, "start_date": "2009-09-01", "completion_date": "2010-11-08", "has_results": true, "last_update_posted_date": "2017-04-06", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 59, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 49 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Peoria", "state": "Arizona" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00982228" }, { "nct_id": "NCT04157738", "title": "A Study of Rapid-Acting Mealtime Insulin in Children and Adolescents With Newly Diagnosed Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Diabetes Mellitus", "Type 1 Diabetes" ], "interventions": [ { "name": "Rapid-Acting Insulin", "type": "DRUG" }, { "name": "Long acting insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "7 Years", "maximum_age": "15 Years", "sex": "ALL", "summary": "7 Years to 15 Years" }, "enrollment_count": 24, "start_date": "2019-11-27", "completion_date": "2020-12-17", "has_results": true, "last_update_posted_date": "2021-09-30", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04157738" }, { "nct_id": "NCT00590226", "title": "Insulin Detemir Versus NPH Insulin In Hospitalized Patients With Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Type 2 Diabetes" ], "interventions": [ { "name": "Detemir + aspart insulin before meals", "type": "DRUG" }, { "name": "NPH insulin + regular insulin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 130, "start_date": "2006-12", "completion_date": "2008-04", "has_results": true, "last_update_posted_date": "2014-06-11", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Chicago, Illinois", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00590226" }, { "nct_id": "NCT01464099", "title": "Bioequivalence of Two NovoLog® Formulations in Subjects With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2008-06", "completion_date": "2008-11", "has_results": false, "last_update_posted_date": "2016-10-28", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 1, "location_summary": "Chula Vista, California", "locations": [ { "city": "Chula Vista", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01464099" }, { "nct_id": "NCT02825251", "title": "Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart Compared to NovoRapid® in Adults With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 472, "start_date": "2016-07-06", "completion_date": "2017-07-21", "has_results": true, "last_update_posted_date": "2019-11-21", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 30, "location_summary": "Encino, California • Fresno, California • Roseville, California + 25 more", "locations": [ { "city": "Encino", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Roseville", "state": "California" }, { "city": "San Mateo", "state": "California" }, { "city": "San Ramon", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02825251" }, { "nct_id": "NCT01819129", "title": "Efficacy and Safety of FIAsp Compared to Insulin Aspart in Combination With Insulin Glargine and Metformin in Adults With Type 2 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Faster-acting insulin aspart", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 881, "start_date": "2013-09-09", "completion_date": "2015-01-22", "has_results": true, "last_update_posted_date": "2019-01-30", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 77, "location_summary": "Glendale, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more", "locations": [ { "city": "Glendale", "state": "Arizona" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01819129" }, { "nct_id": "NCT04880850", "title": "A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Insulin icodec", "type": "DRUG" }, { "name": "Insulin glargine", "type": "DRUG" }, { "name": "Insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 582, "start_date": "2021-05-14", "completion_date": "2022-06-16", "has_results": true, "last_update_posted_date": "2025-12-04", "last_synced_at": "2026-09-29T04:26:45.690Z", "location_count": 52, "location_summary": "Little Rock, Arkansas • Anaheim, California • Concord, California + 44 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Anaheim", "state": "California" }, { "city": "Concord", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Huntington Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04880850" } ] }